NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Summit Therapeutics Inc. (“Summit” or the “Company”) (NASDAQ: SMMT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Summit and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May ...

LOS ANGELES, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The original press release, distributed Tuesday, September 9, 2025, incorrectly stated that a lawsuit was filed against Summit Therapeutics, in the headline and body of the release. The Portnoy Law Firm has commenced an investigation into Summit Therapeutics Inc. concerning alleged securities fraud. The corrected release follows. The Portnoy Law Firm advises Summit Therapeutics Inc. investors  ("Summit" or the "Company") (NASDAQ: SMMT) investors that the firm ...

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT) investors of a class action representing investors that bought securities between March 17, 2022 and September 22, 2022, inclusive (the "Class Period"). Summit investors have until September 24, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney ...

Key Takeaways Summit stock fell 25% after new HARMONi data on its lung cancer drug ivonescimab.Western patients saw a 33% risk reduction, compared with 45% for Asian patients.The FDA has indicated a significant OS benefit is required for drug approval.Shares of Summit Therapeutics (SMMT) tanked 25% yesterday after it reported a final analysis of data from the HARMONi study, which evaluated its investigational antibody ivonescimab in certain patients with non-small cell lung cancer (NSCLC).This analysis show ...

PresentationOperator Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Summit Therapeutics Update Call. [Operator Instructions] It is now my pleasure to turn today's call over to Dave Gancarz, Chief Business and Strategy Officer. Dave, please go ahead. ...

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Summit Therapeutics (NasdaqGM:SMMT) Update / Briefing September 08, 2025 08:00 AM ET Company ParticipantsDave Gancarz - Chief Business & Strategy OfficerH. Jack West - VP - Clinical DevelopmentYigal Nochomovitz - DirectorSalveen Richter - Biotechnology Equity ResearchGreg Wiessner - Biotech Equity Research AssociateCory Kasimov - Senior Managing DirectorManmeet Soni - COO & CFOMohit Bansal - MD & Co-Head - Therapeutics ResearchNone - ExecutiveDaina Graybosch - Senior MD - Immuno-OncologyClara Dong - VP - Eq ...

Summit Therapeutics WCLC Update Call September 8, 2025 8:00am ET Forward Looking Statement Any statements in this press release about the Company's future expectations, plans and prospects, including but not limited to, statements about the clinical and preclinical development of the Company's product candidates, entry into and actions related to the Company's partnership with Akeso Inc., the Company's anticipated spending and cash runway, the therapeutic potential of the Company's product candidates, the p ...

Core Insights - The Phase III HARMONi trial data for ivonescimab plus chemotherapy shows an improving overall survival (OS) trend with a nominal p-value of 0.0332 compared to chemotherapy alone, particularly in North American patients with an OS hazard ratio (HR) of 0.70 [1][4][6] Group 1: Trial Overview - HARMONi trial evaluated ivonescimab plus platinum-doublet chemotherapy against placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who progressed after third-generation EGFR TKI treatment [2][18] - The trial's primary endpoints were progression-free survival (PFS) and overall survival (OS), with previous PD-1 monoclonal antibodies failing to show benefits in similar settings [2] Group 2: Efficacy Results - In the primary analysis, ivonescimab plus chemotherapy showed a median OS of 16.8 months versus 14.0 months for placebo plus chemotherapy, with a hazard ratio of 0.79 (95% CI: 0.62 – 1.01; p=0.057) [4][6] - Longer-term follow-up analysis indicated a median OS of 17.0 months for ivonescimab compared to 14.0 months for placebo in Western patients, with an improved hazard ratio of 0.84 [6][7] - The overall response rate was higher in the ivonescimab arm at 45% compared to 34% in the placebo arm, with a median duration of response of 7.6 months versus 4.2 months [10] Group 3: Safety Profile - Ivonescimab plus chemotherapy demonstrated a manageable safety profile, with 7.3% of patients discontinuing due to treatment-related adverse events (TRAEs) compared to 5.0% in the placebo group [12][13] - The most common TRAEs included anemia and decreases in white blood cell counts, with less than 1% experiencing Grade 3 or higher hemorrhage events [12][13] Group 4: Future Developments - Summit Therapeutics plans to host a conference call on September 8, 2025, to discuss the ivonescimab data presented at the WCLC 2025 [14][30] - The company is engaged in multiple Phase III clinical trials for ivonescimab, including HARMONi-2 and HARMONi-6, which are expected to further evaluate its efficacy [19][20]

Core Viewpoint - H.C. Wainwright has raised the target price for Summit Therapeutics Inc. (SMMT.US) from $44 to $50 while maintaining a "Buy" rating, indicating a positive outlook for the company [1] Company Overview - Summit Therapeutics is a biopharmaceutical company focused on the research and commercialization of innovative therapies aimed at addressing significant unmet medical needs [1] - The company's current clinical development projects primarily target Clostridium difficile infection (CDI) [1] Market Position - The report highlights that now is an opportune time to invest in Summit, as it serves as a partner for CanSino Biologics (09926) in the U.S. market, providing a unique advantage [1] Clinical Data - The report mentions that CanSino's ivonescimab Phase III study HARMONi-A data validates clinical results in China, demonstrating its efficacy superior to Keytruda [1]